Table 2.

Human Immunodeficiency Virus Disease Severity Measures Among Youth Living With Perinatally Acquired Human Immunodeficiency Virus

	YLPHIV (n = 431)
Viral load,a,b copies/mL
≤50	259 (62.1)
>50	158 (37.9)
Viral load,b,c copies/mL	50 (50–100)
Log viral loadb,c	4.83 (1.8)
CD4 count,a,d cells/μL
<200	19 (4.5)
200–499	73 (17.2)
500–1000	274 (64.6)
>1000	58 (13.7)
WHO HIV staginga,e
I	27 (6.5)
II	39 (9.4)
III	246 (59.6)
IV	101 (24.5)
Age at initiation of ART,c,f years	4.8 (1.9–7.4)
Age at initiation of ARTa
0–2 years	161 (37.8)
3–5 years	125 (29.3)
6–14 years	140 (32.9)
Duration on ART,c,f years	9.8 (6.8–11.6)
Current ART regimena
2 × NRTI + NNRTI	241 (55.9)
2 × NRTI + PI	140 (32.5)
Others	50 (11.6)

All continuous variables expressed as median (interquartile range) or mean (SD) and categorical variables as number (%).

Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SD, standard deviation; WHO, World Health Organization; YLPHIV, youth living with perinatally acquired HIV.

^aCategorical variable.

^b14 missing values.

^cContinuous variable.

^d7 missing values.

^e18 missing values.

^f5 missing values.